Background 

Bladder cancer has not seen many new treatment breakthroughs in the last ten years. Some targeted treatments have worked very well for other cancers, like kidney cancer, but they usually do not work for bladder cancer. Rarely, a few patients respond very strongly to these treatments. 

Researchers discovered that one patient with advanced bladder cancer had a complete response to a drug called everolimus because of a change in a specific gene, called TSC1. This study will look closely at how often TSC1 changes appear in bladder cancer and how they interact with other genetic changes. 

What This Research Proposes to Address 

The team studied tumors to see how often the TSC1 gene is altered and what other gene changes occur with it. They also tried find new “biomarkers.” These are signs in the cancer cells that can show whether a patient’s cancer will respond well or poorly to certain treatments. 

To better understand how these gene changes affect bladder cancer, they created mouse models where TSC1 is missing, sometimes combined with another common gene change called TP53. These models can show how bladder cancer grows and spreads when these genes are lost. 

Another part of the project focused on a gene called KDM6A. This gene is often altered together with TSC1. By studying KDM6A in lab cell lines, the researchers wanted to learn how this combination of changes influences bladder cancer development. 

Why This Research Is Important 

The ultimate goal of this project was to better understand the role of TSC1 and other genes in bladder cancer. With this data, doctors may be able to figure out which patients are most likely to benefit from targeted treatments like everolimus. 

Right now, only a few bladder cancer patients respond to these types of drugs. Based on this research, we may be able to find patients who match with the right treatment for their specific cancer. This could lead to more effective and personalized treatment options in the future. 

Final Report Summary

Bladder cancer that has spread, called metastatic bladder cancer, is often treated with chemotherapy, but few other options exist. In a past clinical trial, one patient with bladder cancer responded well to a drug called everolimus, which targets a pathway in cells known as mTOR. Genetic testing showed that this patient had a change, or mutation, in a gene called TSC1, which h0elps control the mTOR pathway. 

To learn more, the researchers studied 199 bladder tumors and looked at over 275 genes that are often changed in cancer. They found that some patients had mutations in the mTOR pathway, including in TSC1. These patients lived longer without their cancer coming back compared to those without these changes. 

The team is now creating mouse models of bladder cancer to study what happens when the TSC1 gene is removed. They want to see if tumors with this mutation are more sensitive to drugs that block the mTOR pathway. 

They are also studying another gene, KDM6A, which often mutates alongside TSC1. By removing these genes in cell lines and mice, they hope to learn how the genes work together and whether blocking the pathway can stop tumor growth. 

None Reported as of August 2025

None Reported as of August 2025

NA